Tema Etfs LLC Increases Stock Position in Becton, Dickinson and Company $BDX

Tema Etfs LLC increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 205.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,444 shares of the medical instruments supplier’s stock after buying an additional 5,006 shares during the period. Tema Etfs LLC’s holdings in Becton, Dickinson and Company were worth $1,393,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of BDX. Bill Few Associates Inc. boosted its holdings in shares of Becton, Dickinson and Company by 0.7% in the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after acquiring an additional 55 shares during the period. Gilbert & Cook Inc. lifted its holdings in Becton, Dickinson and Company by 2.0% during the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock worth $490,000 after purchasing an additional 56 shares in the last quarter. Mendel Money Management boosted its stake in Becton, Dickinson and Company by 2.6% in the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock worth $388,000 after purchasing an additional 58 shares during the period. Focus Financial Network Inc. grew its holdings in Becton, Dickinson and Company by 2.2% during the 3rd quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock valued at $504,000 after buying an additional 58 shares in the last quarter. Finally, Moody National Bank Trust Division grew its holdings in Becton, Dickinson and Company by 2.4% during the 2nd quarter. Moody National Bank Trust Division now owns 2,586 shares of the medical instruments supplier’s stock valued at $445,000 after buying an additional 60 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Argus upped their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Royal Bank Of Canada raised their price target on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a report on Wednesday, December 17th. Piper Sandler reduced their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Finally, Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $207.64.

Becton, Dickinson and Company Trading Down 0.0%

Shares of BDX opened at $202.65 on Tuesday. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The firm has a market cap of $57.74 billion, a price-to-earnings ratio of 34.76, a PEG ratio of 2.24 and a beta of 0.23. The firm has a 50 day moving average price of $193.62 and a 200-day moving average price of $188.59. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The company had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were issued a dividend of $1.05 per share. The ex-dividend date was Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.1%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 72.04%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director directly owned 35,816 shares of the company’s stock, valued at $6,324,389.28. The trade was a 0.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 629 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total value of $123,302.87. Following the completion of the sale, the executive vice president owned 13,105 shares of the company’s stock, valued at $2,568,973.15. The trade was a 4.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 1,052 shares of company stock worth $201,235. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.